Metformin Modulated Conventional and Biochemical Markers in Polycystic Ovarian Women
Omar A. Salman, Entedhar R. Sarhat
Polycystic ovary syndrome (PCOS) is the most common form of chronic female disease associated with androgen excess. The purpose of this study is to evaluate the serum level of Anti-Mullerian Hormone (AMH), 17-hydroxyprogesterone (17-OHP), and Dehydroepiandrosterone sulfate (DHEAS) in women with PCOS and to investigate the effect of metformin on AMH, 17-OHP, and DHEAS. Methods: A total of 261 subjects (141 PCOS and 120 control) were enrolled in the present study. The body mass index is determined before and after therapy. They take metformin 850 mg twice daily for three months and provide fasting blood samples on the second day of menstruation before and after treatment. Hormones quantified before and after metformin therapy. The DHEAS level was significantly higher in PCOS cases compared to controls. After metformin intake, those patients exhibit non-significant differences in DHEAS after metformin treatment. Serum levels of TSH in women with PCOS were significantly elevated compared to the healthy control group. However, the study found no significant difference (p>0.05) in TSH levels in the treated group with metformin compared with pre-treatment. Metformin decreased AMH and 17OHP levels without affecting DHEAS levels in patients with PCOS.
Keywords: Metformin, Polycystic ovarian syndrome, Anti-mullerian hormone, Hydroxyprogesterone, Dehydroepiandrosterone
